Listen to Sten R. Sörensen, CEO of Cereno Scientific, delve into the company’s new strategic focus and share his insights from the company’s capital markets day.
The temperature of Cereno Scientific after major news
Cereno Scientific has recently announced the selection of a rare disease, idiopathic pulmonary fibrosis, as the target indication for its second drug candidate, CS014. Along with the new data for its lead candidate, CS1, this marks a clear shift in strategy and focus: rare diseases that today leave patients without effective treatment options.
Notiser
Nosa Plugs expanderar till Norge
BrainCool pausar stroke-studie
PHI får ny vd
AcouSort utökar europeiskt samarbete
Integrum stärker distribution i Ukraina
NYHETSBREV
NYHETER
Lovande preliminära resultat för Elicera Therapeutics CAR T-cellstudie
Active Biotech stiger på lovande data
Cereno Scientific går framåt på bred front under Q1
Kommande event!
Investing in Life Science
We cover early-stage, growth-stage and late-stage investments. From business angels and seed investors driving medical breakthroughs, to investments empowering promising...
Life Science Summit
The Nordic region’s leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
Du är värd det bästa!
Lås upp vårt premium-innehåll: Bli prenumerant!
Skapa konto
Krönikor
Fruergaard Jørgensen lämnar – något är på tok
Första draget gjort – nu väntar vi på svar
